Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
about
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceImpact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectivesSkeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trialsEnzalutamide for the treatment of metastatic castration-resistant prostate cancer.Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.Development of enzalutamide for metastatic castration-resistant prostate cancer.Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials.Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials.Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
P2860
Q26772883-12A2E0AB-5BA7-4018-B623-848D7AD944A8Q28076911-221B5D4D-21D8-43F0-ADF9-C1AC51E76E69Q31152383-3173D8AC-F6A6-488B-86AD-CA0582F3AE9CQ34484835-113A6995-0CAE-42EC-92FE-8B0DB575BB8FQ38399938-3AEF93F7-E6BA-4226-8FEE-67740D1A2338Q38589130-4A65723A-1BC2-42AA-8070-1EE4CDBEDC70Q38667426-7C5443EB-D298-4048-AA54-3ABAD5B0FB73Q38730792-08FA812D-BCE2-41B1-8099-8D3DCF881B18Q38841082-6024554C-7DB6-476C-BA55-9EC9469A8BB0Q39970827-4E7931BF-4EFA-4E64-A9F0-CF1AE7D0C216Q47644799-6FFFE952-1860-483A-B27F-93CDF46CD0C4Q53700821-98373386-9328-4EF6-A27C-62687B4BBDCFQ55646216-016137CA-8E41-4DDA-A73A-D8FBD8317EB0Q56520077-037F7366-6BCC-4130-AC75-3DD15698152A
P2860
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@en
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@nl
type
label
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@en
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@nl
prefLabel
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@en
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@nl
P2093
P2860
P356
P1433
P1476
Impact of enzalutamide on qual ...... IRM randomized clinical trial.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDU510
P577
2014-10-30T00:00:00Z